209 related articles for article (PubMed ID: 18414477)
1. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.
Towne C; Raoul C; Schneider BL; Aebischer P
Mol Ther; 2008 Jun; 16(6):1018-25. PubMed ID: 18414477
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
[TBL] [Abstract][Full Text] [Related]
4. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
Towne C; Setola V; Schneider BL; Aebischer P
Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
[TBL] [Abstract][Full Text] [Related]
6. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
[TBL] [Abstract][Full Text] [Related]
7. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of metallothionein-I, a copper-regulating protein, attenuates intracellular copper dyshomeostasis and extends lifespan in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase-1.
Tokuda E; Okawa E; Watanabe S; Ono S
Hum Mol Genet; 2014 Mar; 23(5):1271-85. PubMed ID: 24163136
[TBL] [Abstract][Full Text] [Related]
9. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.
Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C
Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.
Foust KD; Salazar DL; Likhite S; Ferraiuolo L; Ditsworth D; Ilieva H; Meyer K; Schmelzer L; Braun L; Cleveland DW; Kaspar BK
Mol Ther; 2013 Dec; 21(12):2148-59. PubMed ID: 24008656
[TBL] [Abstract][Full Text] [Related]
12. Intracellular conformational alterations of mutant SOD1 and the implications for fALS-associated SOD1 mutant induced motor neuron cell death.
Zhang F; Zhu H
Biochim Biophys Acta; 2006 Mar; 1760(3):404-14. PubMed ID: 16431026
[TBL] [Abstract][Full Text] [Related]
13. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis.
Menzies FM; Grierson AJ; Cookson MR; Heath PR; Tomkins J; Figlewicz DA; Ince PG; Shaw PJ
J Neurochem; 2002 Sep; 82(5):1118-28. PubMed ID: 12358759
[TBL] [Abstract][Full Text] [Related]
14. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
[TBL] [Abstract][Full Text] [Related]
15. Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 (
Wang S; Ichinomiya T; Savchenko P; Wang D; Sawada A; Li X; Duong T; Li W; Bonds JA; Kim EJ; Miyanohara A; Roth DM; Patel HH; Patel PM; Tadokoro T; Marsala M; Head BP
Theranostics; 2022; 12(12):5389-5403. PubMed ID: 35910808
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of Hsp27 does not influence disease in the mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Krishnan J; Vannuvel K; Andries M; Waelkens E; Robberecht W; Van Den Bosch L
J Neurochem; 2008 Sep; 106(5):2170-83. PubMed ID: 18624915
[TBL] [Abstract][Full Text] [Related]
17. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.
Li K; Hala TJ; Seetharam S; Poulsen DJ; Wright MC; Lepore AC
Neurobiol Dis; 2015 Jun; 78():12-23. PubMed ID: 25818008
[TBL] [Abstract][Full Text] [Related]
18. Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype.
Nizzardo M; Simone C; Rizzo F; Ulzi G; Ramirez A; Rizzuti M; Bordoni A; Bucchia M; Gatti S; Bresolin N; Comi GP; Corti S
Sci Rep; 2016 Feb; 6():21301. PubMed ID: 26878886
[TBL] [Abstract][Full Text] [Related]
19. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice.
Wang L; Gutmann DH; Roos RP
Hum Mol Genet; 2011 Jan; 20(2):286-93. PubMed ID: 20962037
[TBL] [Abstract][Full Text] [Related]
20. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA.
Wang J; Xu G; Slunt HH; Gonzales V; Coonfield M; Fromholt D; Copeland NG; Jenkins NA; Borchelt DR
Neurobiol Dis; 2005 Dec; 20(3):943-52. PubMed ID: 16046140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
